The study will advance understanding of baricitinib’s potential as a treatment for the virus
News
US expands scope of MSD’s Gardasil
The indication is approved under accelerated approval
US approves first dispersible tablet formulation of Tivicay
The formulation and an expanded indication for Tivicay tablets are currently under review in Europe
AZ signs deal with Europe’s IVA for coronavirus vaccine supply
The drug giant has agreed to supply 400 million doses of the vaccine under the deal
Researchers to test potential COVID-19 treatment in UK
TRV027 targets cell pathways thought to be major drivers of severe illness in COVID-19
NICE backs Rozlytrek for subset of NSCLC patients
Rozlytrek is one of a new group of histology-independent cancer treatments designed to treat tumours regardless of where the primary tumour originates
Novo snaps up cardio-renal group Corvidia
The moves gives the Danish drugmaker access to Corvidia’s lead candidate ziltivekimab
Local authorities in England get funding for test and trace
The funding is designed to help local communities develop and action plans to curb the spread of coronavirus in their areas
EU regulators agree to review LEO’s dermatitis drug
The drug targets a key driver of the underlying inflammation in the condition
NICE rejects Sanofi’s Cablivi in draft guidelines
Trial data does not show whether adding Cablivi to standard care improves either length or quality of life over the long term, the Institute said
NHS accelerates launch of new radiotherapy
The move comes as cancer services face a huge backlog of patients whose treatment has been on pause during the coronavirus pandemic
The Creative Engagement Group buys Cormis
The move is Huntsworth’s first acquisition under the ownership of Clayton, Dubilier & Rice
AbbVie and Genmab link for oncology collaboration
AbbVie will pay Genmab $750 million upfront, and potentially up to $3.15 billion in additional development, regulatory and sales milestone payments
Public launch for ICR, CR UK spinout Monte Rosa
The company aims to target cancer with new drugs that take advantage of protein degradation
Lilly signs up for access to Evox’ tech in R&D deal
Evox’ technology modifies exosomes to deliver drugs to areas currently inaccessible
